GGrantIndex
← Leaderboards

Misty Ward Stevens

Intervexion Therapeutics, Llc

Google Scholar ↗PubMed ↗ORCID ↗
$38,285,082
Attributed
$64,553,944
Total exposure
7
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $11.5M · FY2014–24
$20M$15M$10M$5M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$64,553,944 · 7

By mechanism

U01$64,553,944 · 7

Top collaborators

Others in their field

Top investigators on “Monoclonal Antibodies”

Research focus

Monoclonal AntibodiesAntibodiesClinical ResearchDoseAffinitySafetyPharmaceutical PreparationsMethamphetamineMethamphetamine UsePreparationReportingProtocols DocumentationDesignBrainRattusMeetingsBindingRelapseStability TestingBloodBehavioralBehavior TherapyDrug KineticsClinical Trials

Grant awards (23)

IND-enabling program for a long-acting anti-methamphetamine monoclonal antibody for treating methamphetamine use disorder$4,314,989
U01 · FY2024 · DA · contact PI
OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder$4,609,902
U01 · FY2023 · DA · contact PI
IND-enabling program for a long-acting anti-methamphetamine monoclonal antibody for treating methamphetamine use disorder$4,336,347
U01 · FY2023 · DA · contact PI
OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder$4,570,609
U01 · FY2022 · DA · contact PI
Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization$2,115,968
U01 · FY2022 · DA · contact PI
Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS$1,863,102
U01 · FY2022 · DA · contact PI
IND-enabling program for a long-acting anti-methamphetamine monoclonal antibody for treating methamphetamine use disorder$1,248,915
U01 · FY2022 · DA · contact PI
OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder$4,597,509
U01 · FY2021 · DA · contact PI
Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS$3,750,210
U01 · FY2021 · DA · contact PI
Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization$3,165,675
U01 · FY2021 · DA · contact PI
Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization$3,136,427
U01 · FY2020 · DA · contact PI
Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS$2,492,018
U01 · FY2020 · DA · contact PI
STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy$1,429,307
U01 · FY2019 · DA · contact PI
STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy$938,893
U01 · FY2019 · DA · contact PI
STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy$2,735,856
U01 · FY2018 · DA · contact PI
STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy$4,601,742
U01 · FY2017 · DA · contact PI
Transition to Human Phase 1b Trials: Nonclinical Studies of an Anti-METH mAb$194,975
U01 · FY2017 · DA · contact PI
A Methamphetamine Conjugate Vaccine: From Manufacturing to IND$4,033,814
U01 · FY2016 · DA · contact PI
Transition to Human Phase 1b Trials: Nonclinical Studies of an Anti-METH mAb$2,085,133
U01 · FY2016 · DA · contact PI
A Methamphetamine Conjugate Vaccine: From Manufacturing to IND$1,843,400
U01 · FY2015 · DA · contact PI
Transition to Human Phase 1b Trials: Nonclinical Studies of an Anti-METH mAb$1,594,873
U01 · FY2015 · DA · contact PI
A Methamphetamine Conjugate Vaccine: From Manufacturing to IND$3,606,802
U01 · FY2014 · DA · contact PI
Transition to Human Phase 1b Trials: Nonclinical Studies of an Anti-METH mAb$1,287,478
U01 · FY2014 · DA · contact PI